Saheed Ekundayo Sanyaolu

Mr. Saheed Ekundayo Sanyaolu

Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2022 in Materials
Verified
Journal Article
Open access
PDF file
OAOlutayo Ademola Adeleye
Olutayo Ademola Adeleye
OBOluyemisi A. Bamiro
Oluyemisi A. Bamiro
DADoha Albalawi
Doha Albalawi
AAAmenah S. Al-otaibi
Amenah S. Al-otaibi
HIHaroon Iqbal
Haroon Iqbal
Farid MenaaFarid Menaa
Farid Menaa
Cellulose is a non-toxic, bio-degradable, and renewable biopolymer which is abundantly available in nature. The most common source of commercial microcrystalline cellulose is fibrous wood pulp. Cellulose and its derivatives have found wide commercial applications in the pharmaceutical, cosmetic, food, paper, textile, and engineering industries. This study aims to isolate and characterize cellulose forms from cocoa pod husk (CPH) and to assess its mechanical and disintegration properties as a direct compression excipient in metronidazole tablets. Two isolated cellulose types (i.e., cocoa alpha-cellulose (CAC) and cocoa microcrystalline cellulose (C-MCC)) were compared with avicel (AV). CAC and C-MCC were characterized for their physicochemical properties using Scanning Electron Microscopy (SEM), FTIR spectroscopy, Differential Scanning Calorimetry (DSC), and X-Ray Powder Diffraction (XRD). Metronidazole tablets were produced by direct compression with cellulose. The mechanical and disintegration properties of the tablets were evaluated. CAC and C-MCC yield was 42.3% w/w and 38.25% w/w, respectively. Particle diameters were significantly different with CAC (282.22 μm) > C-MCC (161.32 μm) > AV (72.51 μm). CAC and C-MCC had a better flow than AV. SEM revealed the fibrous nature of the cellulose. FTIR and XRD analysis confirmed the presence of cellulose with crystallinity index of 69.26%, 43.83%, and 26.32% for AV, C-MCC, and CAC, respectively. C-MCC and AV are more crystalline and thermally stable at high temperatures compared to CAC. The mechanical and disintegration properties of C-MCC and AV tablets complied with pharmacopeia specifications. Taken together, C-MCC isolated from CPH displayed some fundamental characteristics suitable for use as a pharmaceutical excipient and displayed better properties compared to that of AV.
1

19 January 2024 in Frontiers in Artificial Intelligence
Verified
Journal Article
Open access
OAObi Peter Adigwe
Obi Peter Adigwe
GOGodspower Onavbavba
Godspower Onavbavba
Saheed Ekundayo SanyaoluSaheed Ekundayo Sanyaolu
Saheed Ekundayo Sanyaolu
Background: Artificial intelligence technology can be applied in several aspects of healthcare delivery and its integration into the Nigerian healthcare value chain is expected to bring about new opportunities. This study aimed at assessing the knowledge and perception of healthcare professionals in Nigeria regarding the application of artificial intelligence and machine learning in the health sector. Methods: A cross-sectional study was undertaken amongst healthcare professionals in Nigeria with the use of a questionnaire. Data were collected across the six geopolitical zones in the Country using a stratified multistage sampling method. Descriptive and inferential statistical analyses were undertaken for the data obtained. Results: Female participants (55.7%) were slightly higher in proportion compared to the male respondents (44.3%). Pharmacists accounted for 27.7% of the participants, and this was closely followed by medical doctors (24.5%) and nurses (19.3%). The majority of the respondents (57.2%) reported good knowledge regarding artificial intelligence and machine learning, about a third of the participants (32.2%) were of average knowledge, and 10.6% of the sample had poor knowledge. More than half of the respondents (57.8%) disagreed with the notion that the adoption of artificial intelligence in the Nigerian healthcare sector could result in job losses. Two-thirds of the participants (66.7%) were of the view that the integration of artificial intelligence in healthcare will augment human intelligence. Three-quarters (77%) of the respondents agreed that the use of machine learning in Nigerian healthcare could facilitate efficient service delivery. Conclusion: This study provides novel insights regarding healthcare professionals' knowledge and perception with respect to the application of artificial intelligence and machine learning in healthcare. The emergent findings from this study can guide government and policymakers in decision-making as regards deployment of artificial intelligence and machine learning for healthcare delivery.

28 March 2025 in Premier Journal of Cardiology
Verified
Journal Article
Open access
Saheed Ekundayo SanyaoluSaheed Ekundayo Sanyaolu
Saheed Ekundayo Sanyaolu
In recent years, artificial intelligence (AI) has emerged as an important technology revolutionizing the diagnosis and prognosis of cardiovascular diseases. In cardiology, machine learning models can reduce the cost and time-to-diagnosis, as well as increase diagnostic precision, consequently improving the quality of care for patients. Therefore, this review provided an overview of innovative models in cardiology-based image analysis for disease diagnosis. Recent reports on studies evaluating the performance of these models were reviewed. Common approaches to training AI models include supervised learning, semi-supervised learning, unsupervised learning, and various other approaches. Logistic regression, support vector machines, random forests, cluster analysis, and neural networks are examples of machine learning architectures used in modern times. AI is used in cardiac magnetic resonance imaging to detect artifacts and assess image quality, as well as to quantify blood flow faster and more accurately. Convoluted neural networks are utilized in echocardiography and electrocardiography to enhance the precision of visualizing cardiac structures and assessing cardiac functions, respectively. AI models in X-ray imaging are employed to identify structural anomalies in the heart and assess their severity. In response to the need for high-quality data while safeguarding patient privacy and confidentiality, specialized databases with comprehensive datasets have been established, such as the UK Biobank and the MIT-BIH Malignant Ventricular Arrhythmia Database. Prospects in machine learning-based screening in cardiology include digital heart winners in precision medicine, explainable AI, and radionics.

10 October 2024 in Public Health Challenges
Verified
Journal Article
Open access
OAObi Peter Adigwe
Obi Peter Adigwe
GOGodspower Onavbavba
Godspower Onavbavba
OAOlajide Joseph Adebola
Olajide Joseph Adebola
AAAnthony Ayeke
Anthony Ayeke
Saheed Ekundayo SanyaoluSaheed Ekundayo Sanyaolu
Saheed Ekundayo Sanyaolu
KAKenneth Anene Agu
Kenneth Anene Agu
Background: Vaccination protects the population against infectious diseases and reduces their transmissibility. Potentials exist for local production of vaccines in Nigeria, as a means of addressing public health needs. However, challenges exist in certain critical aspects which limit development in this area. This study aimed at evaluating the challenges of local vaccines’ manufacturing in Nigeria from the perspectives of relevant stakeholders.Methods: This was a cross‐sectional study. A structured questionnaire was used for data collection. The data obtained from the study were analysed descriptively.Results: More than half of the study participants (55.5%) agreed that significant gaps exist with respect to access to vaccines in Nigeria. Only about one‐quarter of the respondents (25.8%) were of the view that relevant legislative frameworks exist to support government funding in the area of vaccine production. One‐third of the participants (32.3%) expressed confidence in the availability of trained human resources for vaccine production. Close to two‐thirds of the respondents (61.7%) expressed dissatisfaction regarding the current funding for vaccine research and development, and a similar proportion (65.2%) were of the opinion that a lack of local manufacturing capacity contributed to the sub‐optimal access to vaccines. Moreover, two‐thirds (62.3%) disagreed that Nigeria was prepared for future pandemics.Conclusion: Ill‐suited policies, sub‐optimal infrastructure, and inadequate research and development funding, are some factors which the study identified as contributory to the lack of access to vaccines in Nigeria. There is a need to improve incentives, infrastructural development and build human resource capacity for vaccine research and development to enhance local production in Nigeria.

3 April 2025 in Premier Journal of Cardiology
Verified
Journal Article
Open access
Saheed Ekundayo SanyaoluSaheed Ekundayo Sanyaolu
Saheed Ekundayo Sanyaolu
Heart failure is associated with considerable morbidity and mortality, resulting in high healthcare expenditure worldwide. The last decade has witnessed several significant developments and advances in the management of heart failure. To ensure rapid access to a concise overview of existing evidence for clinical decision-making regarding heart failure management, this study aimed to review scientific publications on emerging treatment approaches for heart failure, particularly in the last 10 years. Scientific databases, including PubMed, Scopus, Web of Science, and Cochrane Library, were explored for research articles on the advances in the management of heart failure and its comorbidities. A narrative review approach was employed in this report. Heart failure has multiple etiologies; hence, a critical aspect of its management involves the identification and treatment of the cause, which may include structural defects in the heart or pathologies from other parts of the body. Notable criteria for the classification of heart failure or for risk stratification are classification with the degree of ejection fraction and the New York Heart Association classification of heart failure. Challenges of traditional treatment strategies comprised lack of precision, treatment failure, adverse treatment outcomes, and short survival. In recent years, new drugs have been tested and approved for heart failure management, and some of them are included in the treatment guidelines for heart failure. Furthermore, precision medicine through genome editing and artificial intelligence-based innovations have revolutionized the management of healthcare. However, there are emerging concerns regarding the affordability and accessibility of the new treatment strategies.

26 July 2025 in Premier Journal of Cardiology
Verified
Journal Article
Open access
Saheed Ekundayo SanyaoluSaheed Ekundayo Sanyaolu
Saheed Ekundayo Sanyaolu
DWDiana O. Wilson
Diana O. Wilson
BOBlessing A. Oguntolu
Blessing A. Oguntolu
MSMautin S. Salako
Mautin S. Salako
RARukayat O. Adeyemi
Rukayat O. Adeyemi
Coronary artery disease (CAD) and acute coronary syndrome (ACS) share a pathophysiological basis of myocardial ischemia, primarily driven by atherosclerosis, plaque rupture, and thrombogenesis. Despite advancements in diagnosis and treatment, CAD and ACS continue to pose significant clinical challenges due to variable patient responses, limitations in pharmacological and interventional therapies, and gaps in long-term safety data. Current pharmacologic management integrates conventional agents such as aspirin, clopidogrel, anticoagulants, beta-blockers, and angiotensin-converting enzyme inhibitors. Furthermore, emerging therapies, such as proprotein convertase subtilisin kexin type 9 inhibitors, sodium-glucose co-transporter two inhibitors, RNA-based therapies, and anti-inflammatory agents such as canakinumab, offer innovative approaches to improving patient outcomes and addressing the limitations of traditional therapies. However, adherence remains a challenge, particularly in high-risk patients. Lifestyle modifications and interventional strategies, including percutaneous coronary intervention, coronary artery bypass grafting, transcatheter aortic valve replacement, and hybrid revascularization, provide tailored approaches based on disease severity. Mechanical circulatory support devices, such as Impella pumps, are also critical in managing cardiogenic shock. To optimize CAD and ACS management, a multidisciplinary approach that integrates pharmacological innovations, surgical expertise, algorithm-based interventions, and precision medicine is essential. Improving adherence strategies and refining individualized treatment regimens will be key to advancing cardiovascular care globally.